Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

Abstract: Disclosed in the present disclosure are a novel injection polyaminopolycarboxylic acid-modified abiraterone derivative for treatment of prostate tumor, a pharmaceutical preparation containing the polyaminopolycarboxylic acid-modified abiraterone derivative, a preparation method, and an application. The polyaminopolycarboxylic acid-modified abiraterone derivative has the following structure (I). The polyaminopolycarboxylic acid-modified abiraterone derivative in the present disclosure has good water solubility, can be completely dissolved in an aqueous solution of sodium bicarbonate, is simple and convenient to prepare, high in yield, and suitable for large-scale production, has a remarkable effect in resisting tumors, can be used for treating prostate cancer tumor, and has the characteristics of high efficiency and low toxicity.